In recent studies, GLP-1R agonists were revealed with a beneficial effect on NAFLD through their ability to regulate metabolism, indicating that they may be a new choice for the treatment of NAFLD. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.